An agile, lean and partially in-silico drug discovery pipeline is key to the success of start-up companies that pursue their small molecule drug discovery goals on a limited budget.
We all have billion dollar figures in mind for an approved drug, but the early stage drug discovery, up to an investigational new drug application, consumes only a small fraction of this cost.
In this webinar, Dr. Adrian Schomburg from Eisbach Bio explains how an agile drug discovery platform is a key success factor, especially in a pandemic situation: Tools that Eisbach has lined up for cancer discovery projects were quickly adapted to screen for novel inhibitors of a key SARS-CoV-2 enzyme, from idea to antiviral activity in only two months. These include MD-based and AI-augmented compound docking, visual inspection and refinement, biochemical, ADMET and cell based anti-viral screening as well as PK.
We cordially invite you to join Adrian with us in this exciting webinar.
